Pharmacological Reviews Get Tables of Contents delivered automatically
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Macgregor, J. I.
Right arrow Articles by Jordan, V. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Macgregor, J. I.
Right arrow Articles by Jordan, V. C.

Vol. 50, Issue 2, 151-196, June 1998

Basic Guide to the Mechanisms of Antiestrogen Action

Jennifer I. Macgregor and V. Craig Jordana

Robert H. Lurie Comprehensive Cancer Center, Northwestern University Medical School, Chicago, Illinois

I. Introduction
II. Unresolved Issues in 1984
    A. Species Differences
    B. Differences Between Antiestrogens In Vivo and In Vitro
    C. Antiestrogen Binding Sites
III. The Estrogen Receptor
IV. A Second Receptor
V. Estrogen Receptor
    A. Receptor Functions
    B. Estrogen Action
VI. Estrogen Receptor Regulation
    A. Estrogen Withdrawal
    B. Receptor Regulation
    C. Loss of the Receptor
VII. Antiestrogen Classification
    A. Type I
    B. Type II
VIII. Mechanisms of Antiestrogen Action
    A. Receptor Mutation and Antiestrogens
    B. Interactions with Estrogen Response Elements
IX. Antiestrogens and the Cell Cycle
X. Antiestrogens and Growth Factors
    A. Transforming Growth Factor alpha
    B. Transforming Growth Factor beta
    C. Insulin-Like Growth Factor
XI. Clinical Value of Tamoxifen
    A. Contralateral Breast Cancer
    B. Endocrine Function and Tamoxifen
    C. Tamoxifen and Bone
    D. Tamoxifen and Lipids
XII. Complexity of Antiestrogen Action
    A. Estrogen Receptor-Associated Proteins
    B. Antiestrogen Response Elements
XIII. Concerns with Tamoxifen
    A. Uterine Carcinogenesis
    B. Rat Liver Carcinogenesis
    C. Mechanism of Carcinogenesis
    D. Tamoxifen Metabolism
XIV. Drug Resistance Mechanisms
    A. Metabolic Activation
    B. Mutant Receptors
    C. Alternate Pathways
XV. Clinical Application of New Antiestrogens
    A. Tamoxifen Analogs for Breast Cancer
    B. Pure Antiestrogens for Breast Cancer
    C. Targeted Antiestrogens for Osteoporosis
        1. Raloxifene (also referred to in the literature as LY 156, 758, keoxifene, LY 139, 481-HCL, Evista®).
        2. Droloxifene.
        3. Idoxifene.
XVI. New Compounds and New Opportunities
    A. EM-800
    B. Peripheral Selectivity
XVII. Crystallization of the Raloxifene-Estrogen Receptor Complex
XVIII. Summary and Conclusions
Acknowledgments
References


a   Address for correspondence: V. Craig Jordan, Robert H. Lurie Comprehensive Cancer Center, 8258 Olson Pavilion, Northwestern University Medical School, 303 East Chicago Ave., Chicago, IL 60611.


0031-6997/98/5002-0151$03.00/0
PHARMACOLOGICAL REVIEWS
Copyright © 1998 by The American Society for Pharmacology and Experimental Therapeutics






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition